Skip to content

Live Events
Sign Up / Login

Live Events
Sign Up / Login

Plus Library

By pinki@katapult.biz / February 13, 2025

Speciality

Author / Speaker

Title of Presentation

Type of Media

Event

2024 Event

Clear

Displaying 1,826 - 1,850 of 2,875

«
1
…
72
73
74
75
76
…
115
»

Locally Advanced NSCLC- Radiation Therapy

Locally Advanced NSCLC- Radiation Therapy

Lucas Vitzthum, MD, MAS

Locally Advanced NSCLC- Radiation Therapy

Locally Advanced NSCLC- Radiation Therapy

Lucas Vitzthum, MD, MAS

Surgery for Early-Stage NSCLC

Surgery for Early-Stage NSCLC

Luis A. Godoy, MD, MAS, FACS

Surgery for Early-Stage NSCLC

Surgery for Early-Stage NSCLC

Luis A. Godoy, MD, MAS, FACS

Squamous Cell Carcinoma: What are the Standards and Potential Pathways in Development

Squamous Cell Carcinoma: What are the Standards and Potential Pathways in Development

Luis Corrales-Rodriguez, MD

Challenges in Immunotherapy in NSCLC

Challenges in Immunotherapy in NSCLC

Luis E Raez - MD - FACP - FCCP

Lung Cancer Neoadjuvant and Adjuvant Immunotherapy

Lung Cancer Neoadjuvant and Adjuvant Immunotherapy

Luis E Raez, MD, FACP, FCCP

Lung Cancer Neoadjuvant and Adjuvant Immunotherapy

Lung Cancer Neoadjuvant and Adjuvant Immunotherapy

Luis E Raez, MD, FACP, FCCP

Lung Cancer Neoadjuvant and Adjuvant Immunotherapy

Lung Cancer Neoadjuvant and Adjuvant Immunotherapy

Luis E Raez, MD, FACP, FCCP

Lung Targeted Therapies in NSCLC - EGFR, ALK, and ROS1

Lung Targeted Therapies in NSCLC - EGFR, ALK, and ROS1

Luis E. Raez MD

Lung Targeted Therapies in NSCLC - EGFR, ALK, and ROS1

Lung Targeted Therapies in NSCLC - EGFR, ALK, and ROS1

Luis E. Raez MD

NTRK, Exon 20 insertions, and Potential Novel Pathways in Lung Cancer

NTRK, Exon 20 insertions, and Potential Novel Pathways in Lung Cancer

Luis E. Raez, MD

RET, MET, NTRK

Luis E. Raez, MD

Immunotherapy in Lung Cancer

Immunotherapy in Lung Cancer

Luis E. Raez, MD

Agnostic Tumor Drug Development

Agnostic Tumor Drug Development

Luis E. Raez, MD

Immunotherapy in Lung Cancer

Immunotherapy in Lung Cancer

Luis E. Raez, MD

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

Luis E. Raez, MD

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

Luis E. Raez, MD

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

Luis E. Raez, MD

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

Luis E. Raez, MD

Immunotherapy in Lung Cancer: NEOADJ, ADJ and LA Disease

Immunotherapy in Lung Cancer: NEOADJ, ADJ and LA Disease

Luis E. Raez, MD, FACP

Immunotherapy in Lung Cancer: NEOADJ, ADJ and LA Disease

Immunotherapy in Lung Cancer: NEOADJ, ADJ and LA Disease

Luis E. Raez, MD, FACP

Controversies in Lung Cancer: Neoadjuvant vs Adjuvant IO in Early Stage NSCLC

Controversies in Lung Cancer: Neoadjuvant vs Adjuvant IO in Early Stage NSCLC

Luis E. Raez, MD, FACP

Controversies in Lung Cancer:
Neoadjuvant vs Adjuvant IO in Early Stage NSCLC

Controversies in Lung Cancer: Neoadjuvant vs Adjuvant IO in Early Stage NSCLC

Luis E. Raez, MD, FACP

Utilization of Immunotherapy in the Perioperative Setting

Utilization of Immunotherapy in the Perioperative Setting

Luis E. Raez, MD, FACP, FASCO

«
1
…
72
73
74
75
76
…
115
»

Post navigation

← Previous View

6619 South Dixie Highway #341
Miami, FL 33143

Phone: 305.663.1628
Email: info@meccinc.com

Userful Links

Live Events

Categories

About Us

Why Subscribe
About Us
Accreditation

© 2025 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok